Ranitidine

Active ingredient: Ranitidine Hydrochloride

In short: Ranitidine Tablets are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks.

LabelAtland Pharmaceuticals, LLC
Label updatedSep 25, 2026

What is Ranitidine used for?

Ranitidine Tablets are indicated in:

Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of Ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks.

Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo – controlled comparative studies have been carried out for periods longer than 1 year.

The treatment of pathological hypersecretory conditions. (e.g., Zollinger-Ellison syndrome and systemic mastocytosis).

Short-term treatment of active, benign gastric ulcers. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks.

Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year.

Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets USP, 150 mg twice daily.

Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets USP, 150 mg 4 times daily.

Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. …

Ranitidine dosage

Active Duodenal Ulcer:The current recommended adult oral dosage of Ranitidine Tablets for duodenal ulcer is 150 mg twice daily. An alternative dosage of 300 mg once daily after the evening meal or at bedtime can be used for patients in whom dosing convenience is important. The advantages of one treatment regimen compared with the other in a particular patient population have yet to be demonstrated .

Smaller doses have been shown to be equally effective in inhibiting gastric acid secretion in US studies, and several foreign trials have shown that 100 mg twice daily is as effective as the 150 mg dose.

Antacid should be given as needed for relief of pain .

Maintenance of Healing of Duodenal Ulcers:The current recommended adult oral dosage is 150 mg at bedtime.

Pathological Hypersecretory Conditions (such as Zollinger - Ellison syndrome):The current recommended adult oral dosage is 150 mg twice daily. In some patients it may be necessary to administer Ranitidine Tablets USP, 150 mg doses more frequently. Dosages should be adjusted to individual patient needs and should continue as long as clinically indicated. Dosages up to 6 g/day have been employed in patients with severe disease.

Benign Gastric Ulcer:The current recommended adult oral dosage is 150 mg twice daily.

Maintenance of Healing of Gastric Ulcers:The current recommended adult oral dosage is 150 mg at bedtime.

GERD:The current recommended adult oral dosage is 150 mg twice daily.

Erosive Esophagitis:The current recommended adult oral dosage is 150 mg 4 times daily.

Maintenance of Healing of Erosive Esophagitis:The current recommended adult oral dosage is 150 mg twice daily.

Pediatric Use:The safety and effectiveness of Ranitidine Tablets have been established in the age group of 1 month to 16 years. There is insufficient information about the pharmacokinetics of Ranitidine Tablets in neonatal patients (less than 1 month of age) to make dosing recommendations.

The following 3 subsections provide dosing information for each of the pediatric indications.

Treatment of Duodenal and Gastric Ulcers:

The recommended oral dose for the treatment of active duodenal and gastric ulcers is 2 to 4 mg/kg twice daily to a maximum of 300 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients.

Maintenance of Healing of Duodenal and Gastric Ulcers:

The recommended oral dose for the maintenance of healing of duodenal and gastric ulcers is to 2 to 4 mg/kg once daily to a maximum of 150 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients. …

Warnings & precautions

Do not take this medicine if: Ranitidine Tablets are contraindicated for patients known to have hypersensitivity to the drug or any of the ingredients .

General:

Symptomatic response to therapy with Ranitidine Tablets does not preclude the presence of gastric malignancy.

Since Ranitidine Tablets are excreted primarily by the kidney, dosage should be adjusted in patients with impaired renal function . Caution should be observed in patients with hepatic dysfunction since Ranitidine Tablets are metabolized in the liver.

Rare reports suggest that Ranitidine Tablets may precipitate acute porphyric attacks in patients with acute porphyria. Ranitidine Tablets should therefore be avoided in patients with a history of acute porphyria.

This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Laboratory Tests:False-positive tests for urine protein with MULTISTIX

Ā® may occur during therapy with Ranitidine Tablets, and therefore testing with sulfosalicylic acid is recommended.

Drug Interactions:Ranitidine has been reported to affect the bioavailability of other drugs through several different mechanisms such as competition for renal tubular secretion, alteration of gastric pH and inhibition of cytochrome P

450 enzymes.

Procainamide:

Ranitidine, a substrate of the renal organic cation transport system, may affect the clearance of other drugs eliminated by this route. High doses of ranitidine (e.g., such as those used in the treatment of Zollinger-Ellison syndrome) have been shown to reduce the renal excretion of procainamide and N-acetylprocainamide resulting in increased plasma levels of these drugs. …

Ranitidine side effects

The following have been reported as events in clinical trials or in the routine management of patients treated with Ranitidine Tablets. The relationship to therapy with Ranitidine Tablets has been unclear in many cases. Headache, sometimes severe, seems to be related to administration of Ranitidine Tablets.

Central Nervous System:Rarely, malaise, dizziness, somnolence, insomnia and vertigo. Rare cases of reversible mental confusion, agitation, depression, and hallucinations have been reported, predominantly in severely ill elderly patients. Rare cases of reversible blurred vision suggestive of a change in accommodation have been reported. Rare reports of reversible involuntary motor disturbances have been received.

Cardiovascular:As with other H

2-blockers, rare reports of arrhythmias such as tachycardia, bradycardia, atrioventricular block, and premature ventricular beats.

Gastrointestinal:Constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain and rare reports of pancreatitis.

Hepatic:There have been occasional reports of hepatocellular, cholestatic, or mixed hepatitis, with or without jaundice. In such circumstances, ranitidine should be immediately discontinued. These events are usually reversible, but in rare circumstances death has occurred. Rare cases of hepatic failure have also been reported. …

About this medicine

Ranitidine Tablets USP are available for oral administration containing 150 mg or 300 mg of ranitidine. The active ingredient in Ranitidine Tablets USP, 150 mg and 300 mg is Ranitidine hydrochloride (HCl), USP, a histamine H

2-receptor antagonist.

Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N’-methyl-2-nitro-1,1-ethenediamine, HCl. It has the following structure:

The empirical formula is C

13H

22N

4O

3S.HCl, representing a molecular weight of 350.87.

Ranitidine HCl is white to pale yellow, crystalline, practically odorless powder, sensitive to light and moisture. Melts at about 140°C with decomposition.

Ranitidine is available as 150 mg and 300 mg tablets for oral administration. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fcf27c99-8bd4-41fb-bff8-38fed9de76d9. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine